Search results for "survival analysi"

showing 10 items of 752 documents

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?

2019

BACKGROUND & AIMS Sarcopenia has emerged as a prognostic parameter in numerous cancer entities. Current research favours its role as a determining factor for overall survival (OS) in patients with intrahepatic cholangiocarcinoma (ICC); however, it is unclear whether sarcopenia is a truly independent survival predictor if combined with established prognostic factors. METHODS Between 1997-2018, 417 patients with histopathologically confirmed ICC were referred to our centre, of whom 293 were included in this study. Cross-sectional imaging, laboratory examinations and histopathological reports were retrospectively analysed. Psoas muscle index (PMI) as easy-to-measure marker of sarcopenia was ca…

MaleSarcopeniamedicine.medical_specialtyGastroenterologyResectionCholangiocarcinoma03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicinemedicineHumansIn patientIntrahepatic CholangiocarcinomaAgedPsoas MusclesRetrospective StudiesUnivariate analysisHepatologybusiness.industryCancerMiddle AgedPrognosismedicine.diseaseMagnetic Resonance ImagingSurvival AnalysisPredictive valueBile Duct Neoplasms030220 oncology & carcinogenesisSarcopeniaMultivariate AnalysisCohortFemale030211 gastroenterology & hepatologyTomography X-Ray ComputedbusinessLiver International
researchProduct

p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospect…

2002

p53 gene alterations are among the most common events observed in colorectal cancer,and are accompanied frequently by DNA aneuploidy and high proliferative activity. The prognostic significance of such mutations remains controversial. We prospectively evaluated the prognostic significance of p53 mutations, DNA-ploidy, and S phase fraction (SPF) in a consecutive series of 160 colorectal cancer patients (median follow-up 71 months). Tumor DNA was screened for p53 mutations by PCR/single-strand conformational polymorphism/sequencing. DNA-ploidy and SPF were assessed by DNA flow cytometry. p53 mutations were detected in 68 of 160 (42.5%) cases. In 56% (38 of 68) of these, p53 mutations were fou…

MaleSettore MED/06 - Oncologia Medicaprotein p53S PhaseBiomarkers TumorHumansProspective StudiesCodonAgedPloidiesPolymorphism GeneticDNA NeoplasmExonsDNAMiddle AgedGenes p53PrognosisSurvival AnalysisProtein Structure TertiaryItalyMultivariate AnalysisMutationFemaleCarrier ProteinsColorectal NeoplasmsFollow-Up Studies
researchProduct

The C(-260)T gene polymorphism in the promoter of the CD14 monocyte receptor gene is not associated with acute myocardial infarction.

2003

CD surface molecules mediates cell activation and signaling. In particular, CD14 on blood monocytes mediate monocyte/macrophage activation by lipopolysaccharide. Lipopolysaccharide and its receptor, CD14, have been implicated in atherogenesis. It has been recently shown that a C(-260)T polymorphism in the promoter of the CD14 receptor may be a risk factor for coronary artery disease. Recently this association has been questioned because no increased risk was found with the T allele, even in the homozygous state. In the present study we investigated a possible association between the C(-260)T polymorphism in the CD14 promoter and acute myocardial infarction. Two hundred and thrteen patients …

MaleSettore MED/09 - Medicina InternaGenotypeCD14Clinical BiochemistryLipopolysaccharide ReceptorsMyocardial InfarctionAntigens CD14Polymorphism Single NucleotideGeneral Biochemistry Genetics and Molecular BiologyCytosineGene FrequencyReference ValuesRisk FactorsGenotypemedicineHumansReference ValuePolymorphismAlleleReceptorPromoter Regions GeneticBiochemistry Genetics and Molecular Biology (all)business.industryRisk FactorMedicine (all)MonocyteSmokingCase-control studyGeneral MedicineMiddle AgedMolecular biologySurvival AnalysisGenotype frequencymedicine.anatomical_structureImmunologySettore MED/26 - NeurologiaFemaleSurvival AnalysiGene polymorphismCD14Cell activationbusinessThymineHumanClinical and experimental medicine
researchProduct

Empirical study of the dependence of the results of multivariable flexible survival analyses on model selection strategy

2008

Flexible survival models, which avoid assumptions about hazards proportionality (PH) or linearity of continuous covariates effects, bring the issues of model selection to a new level of complexity. Each ‘candidate covariate’ requires inter-dependent decisions regarding (i) its inclusion in the model, and representation of its effects on the log hazard as (ii) either constant over time or time-dependent (TD) and, for continuous covariates, (iii) either loglinear or non-loglinear (NL). Moreover, ‘optimal’ decisions for one covariate depend on the decisions regarding others. Thus, some efficient model-building strategy is necessary. We carried out an empirical study of the impact of the model …

MaleStatistics and ProbabilityEpidemiologyAge at diagnosisAdenocarcinomaEmpirical researchRisk FactorsStomach NeoplasmsCovariateStatisticsEconometricsHumansRegistriesSurvival analysisAgedParametric statisticsMathematicsModels StatisticalModel selectionMultivariable calculusAge FactorsMiddle AgedPrognosisSurvival AnalysisMultivariate AnalysisFemaleFranceLog-linear modelStatistics in Medicine
researchProduct

A flexible approach to the crossing hazards problem

2010

We propose a simple and flexible framework for the crossing hazards problem. The method is not confined to two-sample problems, but may also work with continuous exposure variables whose effect changes its sign at some time-point of the observed follow-up time. Penalized partial likelihood estimation relies upon the assumption of a smooth hazard ratio via low-rank basis splines with a conventional difference penalty to ensure smoothness, and additional ad hoc penalties to obtain restricted estimates useful in the context of crossing hazards. The framework naturally also leads to a statistical test that has good power for revealing a global effect under several alternatives, including crossi…

MaleStatistics and ProbabilityMathematical optimizationBiometryEpidemiologyContext (language use)Time-varying effectSimple (abstract algebra)P-splineHumansCrossing pointProportional Hazards ModelsMathematicsStatistical hypothesis testingLikelihood FunctionsSmoothnessBasis (linear algebra)Work (physics)Survival AnalysisCrossing hazardPower (physics)FemaleRestricted estimationSettore SECS-S/01 - StatisticaAlgorithmsSign (mathematics)
researchProduct

INTERSPECIFIC AGGRESSION CAUSES NEGATIVE SELECTION ON SEXUAL CHARACTERS

2005

Interspecific aggression originating from mistaken species recognition may cause selection on secondary sexual characters, but this hypothesis has remained untested. Here we report a field experiment designed to test directly whether interspecific aggression causes selection on secondary sexual characters, wing spots, in wild damselfly populations. Males of Calopteryx virgo are more aggressive toward males of C. splendens with large than with small wing spots. This differential interspecific aggression may cause negative selection on wing spot size. Indeed, our results show that directional survival selection on wing spot size of C. splendens males was changed by experimental removal of C. …

MaleSympatryInsectaZoologyNegative selectionDamselflymedicineCharacter displacementGeneticsAnimalsWings AnimalBody Weights and MeasuresSelection GeneticFinlandSelection (genetic algorithm)Ecology Evolution Behavior and SystematicsAnalysis of VarianceSex CharacteristicsbiologyPigmentationDirectional selectionEcologyAggressionInterspecific competitionbiology.organism_classificationSurvival AnalysisAggressionGenetics Populationmedicine.symptomGeneral Agricultural and Biological SciencesEvolution
researchProduct

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspi…

2009

The prognosis for thalassemia major has dramatically improved in the last two decades. However, many transfusion-dependent patients continue to develop progressive accumulation of iron. This can lead to tissue damage and eventually death, particularly from cardiac disease. Previous studies that investigated iron chelation treatments, including retrospective and prospective non-randomised clinical trials, suggested that mortality, due mainly to cardiac damage, was reduced or completely absent in patients treated with deferiprone (DFP) alone or a combined deferiprone-deferoxamine (DFP-DFO) chelation treatment. However, no survival analysis has been reported for a long-term randomised control …

MaleThalassemiaKaplan-Meier Estimatelaw.inventionchemistry.chemical_compoundRandomized controlled triallawCause of DeathNeoplasmsDeferiproneProspective StudiesChildCause of deathHazard ratioHematologyMiddle AgedCombined Modality TherapySurvival RateThalassemia survival chelation treatment trial thalassemia majorCombinationSplenectomyMolecular MedicineDrug Therapy CombinationFemaleDeferiproneAdultmedicine.medical_specialtyAdolescentPyridonesDeferoxamineIron Chelating AgentsYoung AdultDrug TherapyInternal medicinemedicineHumansBlood TransfusionAdolescent; Adult; Blood Transfusion; Cause of Death; Chelation Therapy; Child; Combined Modality Therapy; Deferoxamine; Drug Therapy; Combination; Female; Heart Failure; Humans; Iron Chelating Agents; Kaplan-Meiers Estimate; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prospective Studies; Pyridones; Splenectomy; Survival Rate; Young Adult; beta-ThalassemiaMolecular BiologySurvival rateKaplan-Meiers EstimateSurvival analysisProportional Hazards ModelsHeart Failurebusiness.industryProportional hazards modelbeta-ThalassemiaCell Biologymedicine.diseaseChelation TherapySurgerychemistrybusiness
researchProduct

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

2020

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions

MaleTime FactorsDiseaseInflammatory bowel diseaseInflammatory bowel diseasesurgeryAnti-TNFBiological Factors0302 clinical medicineAnti-TNF Immunosuppressants Inflammatory bowel disease SurgeryCrohn DiseaseimmunosuppressantsRisk Factorsanti‐TNFGastroenterologyAge FactorsMiddle AgedUlcerative colitisNatural history030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyMedicinaDisease-Free Survival03 medical and health sciencesEarly surgeryYoung AdultGastrointestinal Agentsinflammatory bowel diseaseInternal medicinemedicineHumansSurvival analysisRetrospective StudiesHepatologybusiness.industryTumor Necrosis Factor-alphamedicine.diseasedigestive system diseasesInfliximabImmunosuppressantsSurgeryColitis Ulcerativebusiness
researchProduct

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (R…

2015

Background: VEGF and VEGF receptor-2-mediated angiogenesis contribute to hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal antibody and VEGF receptor-2 antagonist. We aimed to assess the safety and efficacy of ramucirumab in advanced hepatocellular carcinoma following first-line therapy with sorafenib. Methods: In this randomised, placebo-controlled, double-blind, multicentre, phase 3 trial (REACH), patients were enrolled from 154 centres in 27 countries. Eligible patients were aged 18 years or older, had hepatocellular carcinoma with Barcelona Clinic Liver Cancer stage C disease or stage B disease that was refractory or not amenable to locoregional therapy…

MaleTime FactorsKaplan-Meier EstimateGastroenterologyLiver diseaseClinical endpoint610 Medicine & healthramucirumab sorafenib HCCAged 80 and overeducation.field_of_studyLiver NeoplasmsRemission InductionAntibodies MonoclonalMiddle AgedSorafenibTreatment OutcomeOncologyLiver NeoplasmHepatocellular carcinomaFemaleSurvival AnalysiHumanmedicine.drugAdultNiacinamidePhenylurea CompoundSorafenibmedicine.medical_specialtyCarcinoma HepatocellularTime FactorPopulationAntibodies Monoclonal HumanizedPlaceboDisease-Free SurvivalDrug Administration ScheduleFollow-Up StudieRamucirumabDouble-Blind MethodInternal medicineConfidence IntervalsmedicineCarcinomaHumanseducationProportional Hazards ModelsAgedDose-Response Relationship Drugbusiness.industryPhenylurea CompoundsPatient Selectionmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryProportional Hazards ModelbusinessConfidence IntervalFollow-Up StudiesThe Lancet Oncology
researchProduct